Cargando…
Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma
BACKGROUND: Chemoradioimmunotherapy of patients with pancreatic adenocarcinoma from the CapRI trial did not show any benefit of interferon-α in addition to a 5-fluorouracil (5FU)-based treatment. The aim of this study was to identify immunological parameters in patients from this trial to be used fo...
Autores principales: | Karakhanova, S, Ryschich, E, Mosl, B, Harig, S, Jäger, D, Schmidt, J, Hartwig, W, Werner, J, Bazhin, A V |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366903/ https://www.ncbi.nlm.nih.gov/pubmed/25742476 http://dx.doi.org/10.1038/bjc.2015.72 |
Ejemplares similares
-
Influence of Interferon-Alpha Combined with Chemo (Radio) Therapy on Immunological Parameters in Pancreatic Adenocarcinoma
por: Karakhanova, Svetlana, et al.
Publicado: (2014) -
Effects of opioids on immunologic parameters that are relevant to anti-tumour immune potential in patients with cancer: a systematic literature review
por: Boland, J W, et al.
Publicado: (2014) -
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma
por: Alhasan, Sari F, et al.
Publicado: (2016) -
Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma
por: Liles, J S, et al.
Publicado: (2011) -
Metronomic gemcitabine suppresses tumour growth, improves perfusion, and reduces hypoxia in human pancreatic ductal adenocarcinoma
por: Cham, K K Y, et al.
Publicado: (2010)